Blueprint Medicines(BPMC) - 2024 Q4 - Earnings Call Presentation

Blueprint Medicines Driving growth and innovation with operational excellence Fourth quarter and full-year 2024 financial results February 13, 2025 Fourth quarter and full-year 2024 financial results INTRODUCTION AYVAKIT PERFORMANCE Kate Haviland Chief Executive Officer Philina Lee, PhD Chief Commercial Officer Becker Hewes, MD Chief Medical Officer FINANCIAL RESULTS Mike Landsittel Chief Financial Officer 2 CLINICAL 3 2025 guidance progresses AYVAKIT toward $2 billion by 2030$53 $111$204 $479 2021 2022 2 ...